These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 1397716

  • 1. Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects.
    Fulcher GR, Walker M, Catalano C, Agius L, Alberti KG.
    Diabetes; 1992 Nov; 41(11):1400-8. PubMed ID: 1397716
    [Abstract] [Full Text] [Related]

  • 2. Acipimox increases glucose disposal in normal man independent of changes in plasma nonesterified fatty acid concentration and whole-body lipid oxidation rate.
    Fulcher GR, Walker M, Farrer M, Johnson AS, Alberti KG.
    Metabolism; 1993 Mar; 42(3):308-14. PubMed ID: 8487648
    [Abstract] [Full Text] [Related]

  • 3. The effects of changes in plasma nonesterified fatty acid levels on oxidative metabolism during moderate exercise in patients with non-insulin-dependent diabetes mellitus.
    Akanji AO, Osifo E, Kirk M, Hockaday TD.
    Metabolism; 1993 Apr; 42(4):426-34. PubMed ID: 8487664
    [Abstract] [Full Text] [Related]

  • 4. The role of plasma non-esterified fatty acids during exercise in type 2 diabetes mellitus.
    Berrish TS, Elliott C, Cooper BG, Reed JW, Orskov H, Alberti KG, Walker M.
    Diabet Med; 1993 Mar; 10(2):152-8. PubMed ID: 8458192
    [Abstract] [Full Text] [Related]

  • 5. Effects of an acute decrease in non-esterified fatty acid levels on muscle glucose utilization and forearm indirect calorimetry in lean NIDDM patients.
    Piatti PM, Monti LD, Davis SN, Conti M, Brown MD, Pozza G, Alberti KG.
    Diabetologia; 1996 Jan; 39(1):103-12. PubMed ID: 8720610
    [Abstract] [Full Text] [Related]

  • 6. Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus.
    Vaag A, Skött P, Damsbo P, Gall MA, Richter EA, Beck-Nielsen H.
    J Clin Invest; 1991 Oct; 88(4):1282-90. PubMed ID: 1918378
    [Abstract] [Full Text] [Related]

  • 7. Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes.
    Saloranta C, Groop L, Ekstrand A, Franssila-Kallunki A, Eriksson J, Taskinen MR.
    Diabet Med; 1993 Dec; 10(10):950-7. PubMed ID: 8306591
    [Abstract] [Full Text] [Related]

  • 8. Acute metabolic and hormonal responses to the inhibition of lipolysis in non-obese patients with non-insulin-dependent (type 2) diabetes mellitus: effects of acipimox.
    Fulcher GR, Walker M, Catalano C, Farrer M, Alberti KG.
    Clin Sci (Lond); 1992 May; 82(5):565-71. PubMed ID: 1317767
    [Abstract] [Full Text] [Related]

  • 9. Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.
    Davoren PM, Kelly W, Gries FA, Hubinger A, Whately-Smith C, Alberti KG.
    Metabolism; 1998 Mar; 47(3):250-6. PubMed ID: 9500558
    [Abstract] [Full Text] [Related]

  • 10. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.
    Worm D, Henriksen JE, Vaag A, Thye-Rønn P, Melander A, Beck-Nielsen H.
    J Clin Endocrinol Metab; 1994 Mar; 78(3):717-21. PubMed ID: 8126147
    [Abstract] [Full Text] [Related]

  • 11. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects.
    Halberstam M, Cohen N, Shlimovich P, Rossetti L, Shamoon H.
    Diabetes; 1996 May; 45(5):659-66. PubMed ID: 8621019
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of lipolysis decreases lipid oxidation and gluconeogenesis from lactate but not fasting hyperglycemia or total hepatic glucose production in NIDDM.
    Puhakainen I, Yki-Järvinen H.
    Diabetes; 1993 Dec; 42(12):1694-9. PubMed ID: 8243814
    [Abstract] [Full Text] [Related]

  • 13. Peripheral and hepatic insulin sensitivity in non-insulin-dependent diabetes mellitus: effect of nonesterified fatty acids.
    Walker M, Agius L, Orskov H, Alberti KG.
    Metabolism; 1993 May; 42(5):601-8. PubMed ID: 8492715
    [Abstract] [Full Text] [Related]

  • 14. Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM.
    Saloranta C, Taskinen MR, Widen E, Härkönen M, Melander A, Groop L.
    Diabetes; 1993 Nov; 42(11):1559-66. PubMed ID: 8405695
    [Abstract] [Full Text] [Related]

  • 15. Contribution of obesity to defects of intracellular glucose metabolism in NIDDM.
    Chung JW, Suh KI, Joyce M, Ditzler T, Henry RR.
    Diabetes Care; 1995 May; 18(5):666-73. PubMed ID: 8586004
    [Abstract] [Full Text] [Related]

  • 16. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
    Pontiroli AE, Manzoni MF, Malighetti ME, Lanzi R.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3998-4001. PubMed ID: 8923850
    [Abstract] [Full Text] [Related]

  • 17. Glucose metabolism during the starved-to-fed transition in obese patients with NIDDM.
    Féry F, Balasse EO.
    Diabetes; 1994 Dec; 43(12):1418-25. PubMed ID: 7958493
    [Abstract] [Full Text] [Related]

  • 18. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects.
    Santomauro AT, Boden G, Silva ME, Rocha DM, Santos RF, Ursich MJ, Strassmann PG, Wajchenberg BL.
    Diabetes; 1999 Sep; 48(9):1836-41. PubMed ID: 10480616
    [Abstract] [Full Text] [Related]

  • 19. Metabolic effect of decreasing nonesterified fatty acid levels with acipimox in hyperthyroid patients.
    Park KS, Kim CH, Lee MK, Shin CS, Park DJ, Kim SY, Cho BY, Lee HK.
    Metabolism; 1999 Oct; 48(10):1318-21. PubMed ID: 10535397
    [Abstract] [Full Text] [Related]

  • 20. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
    Bajaj M, Suraamornkul S, Romanelli A, Cline GW, Mandarino LJ, Shulman GI, DeFronzo RA.
    Diabetes; 2005 Nov; 54(11):3148-53. PubMed ID: 16249438
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.